Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access